M&A / Property
DRI Healthcare Comments on Viridian's FDA Approval and Launch of Lumvoa(TM) (veligrotug-vvze)
FDA approval on schedule validates $300M Viridian thesis; milestone payment is expected cash outflow for long-dated royalty stream.
Executive Summary
- DRI Healthcare Trust confirmed that Viridian Therapeutics received FDA approval for Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease (TED).
- Under the terms of an existing royalty agreement, DRI will make a one-time milestone payment of $75 million to Viridian.
- DRI holds a tiered royalty interest on annual U.S. net sales of the TED franchise.
- The approval marks the first TED treatment with labeling data for both active and chronic forms of the disease.
- Management highlighted support for Viridian's second-generation candidate, elegrobart, currently in development as a subcutaneous auto-injector.
- First commercial sale is expected shortly post-approval, with the first royalty receipt occurring one quarter later.
Material Impact
- The FDA approval and $75 million milestone payment are fully consistent with prior management guidance and the October 2025 transaction terms. The cash outflow is expected and budgeted. The stock's +5.8% run-up into the print indicates the market had already priced in a successful approval. There is no new information that would trigger a material re-rating. The news is Routine - Positive, confirming execution on a key pipeline catalyst while setting the stage for future royalty cash flows.
DHT · Price
More from NaN
May 14, 2026 · 17:00